Ulf Schnetzke

11PUBLICATIONS
60CO-AUTHORS
Solid tumoursGene and molecular therapyMedical mycologyMedical infection agents (incl. prions)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 26, 2026
Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.

|Jan 29, 2026
Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.

Maximilian Fleischmann, Ole Hansen, Diana Voigtländer

|Oct 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner

|Jul 09, 2024
Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy.

Ulf Schnetzke, Mike Fischer, Christoph Röllig

|Jan 18, 2024
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis.

Johanna Knauft, Thomas Schenk, Thomas Ernst

|Jan 31, 2022
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.

Maximilian Fleischmann, Sebastian Scholl, Jochen J Frietsch

Pageof 2

Frequent Collaborators

2 joint publications

Andreas Hochhaus

1 joint publications

Thomas Ernst

1 joint publications

Paul La Rosée

1 joint publications

Sebastian Birndt